Post by Infinity Bio, Inc.

Antibodies are a detailed ledger of past and ongoing immune responses, a crucial window into health and disease. The challenge has been reading it at scale. Until now. MIPSA, the core technology behind Infinity Bio's antibody reactome platform, reads that ledger by turning it into DNA you can sequence: • Generate the library: MIPSA builds large, comprehensive panels of DNA-barcoded full-length protein and rationally designed peptide antigens spanning viral, allergen, non-viral microbial, and human antigens • Bind and capture: the library mixes with a biospecimen, antibodies bind their targets in solution, and the antibody-bound antigens are captured • Sequence and analyze: their unique DNA barcodes are sequenced, and a bioinformatics pipeline quantifies each antigen reactivity against a set of controls That is the foundation of Antibody Reactomics: immune responses associated with key health outcomes, at population scale. Interested in the interplay of environment, inflammation, and immunity? Watch the explainer video below.

Video Content